drugset / Trial / NCT02483455

ALC-919 For The Treatment Of Common Warts

NCT02483455 ↗

Phase 2 Completed 21 enrolled Veloce BioPharma LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single-center, randomized, double blind, vehicle-controlled phase 2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment.

Timeline

Start
2015-04
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ALC-919 Unknown — Topical

Indications